UTI - Urinary Tract InfectionNCT07189429
Clinical Impact Analysis of PA-100 AST in a Spanish GP Setting
A study testing PA-100 AST in people with UTI - Urinary Tract Infection and UTI - Lower Urinary Tract Infection, run by Sysmex Europe GmbH at 1 site in Spain.
Trial summary
Assessment of workflow implications of the PA-100 AST System. Using well-defined data collection protocols, the study comprises the following: Collection of clean-catch midstream urine samples Measurement of specimens on the PA-100 AST System o Antibiotics tested: Amoxicillin/clavulanic acid (AMC), Ciprofloxacin… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection, AMR
- What is being tested?
- PA-100 AST
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 199 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jul 2024to 30 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients were recruited according to the following criteria: non-pregnant female, >18 years old, presenting with acute UTI symptoms that had been present for < 7 days (symptoms according to the current guidelines [EAU]), with no antibiotic treatment within the previous 7 days, positive urine dipstick for leukocyte esterase (LEU) and/or nitrites (NIT) and who provided a clean-catch mid-stream urine sample.
Who cannot join
- Withdraw of consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: PA-100 Workflow Assessment
Assessment of workflow implications of the PA-100 AST System.
Using well-defined data collection protocols, the study comprises the following:
- Collection of clean-catch midstream urine samples
- Measurement of specimens on the PA-100 AST System
- Antibiotics tested: Amoxicillin/clavulanic acid (AMC), Ciprofloxacin (CIP), Trimethoprim (TRI), Fosfomycin (FOS) and Nitrofurantoin (NIT)
- Treatment of patients according to the results of the tests on the PA-100 AST System
- Collection of data about patient treatment and antibiotic prescription when the PA-100 AST System is not used (study baseline)
- Collection of patient related information
- Collection of workflow-related information, including doctors and nurses at the test location
- Evaluation of changes in the prescription behaviour when using the PA-100 AST System, compared to current practice at the Test Location
Read the detailed description
Uncomplicated cystitis in females is among the most frequent community-acquired infections. Urinary tract infection (UTI) is classified as uncomplicated if it occurs in patients with a structurally and functionally normal urinary tract in otherwise healthy, non-pregnant women. Such acute uncomplicated UTIs occur frequently and are associated with high morbidity. Approximately one third of women up to 24 years of age have experienced uncomplicated UTI.
The current gold standard for UTI diagnosis is urine culture of a midstream, clean-catch urine specimen, followed by antibiotic susceptibility testing (AST). UTI patients are often treated empirically with antibiotics, and most guidelines recommend starting antibiotic treatment without or before urine culture and AST results become available. This results in patient treatment without laboratory evidence or at least in a delay of targeted antibacterial therapy by approximately 48 h, when applicable. Due to the continually changing local rates of antimicrobial resistance, empiric treatments do not ensure appropriate stewardship and can result in therapeutic failure.
Therefore, rapid and accurate diagnosis, leading to evidence-based treatment, is essential to achieve a timely and effective therapy.
With antibiotic resistance rates for common antibiotics reaching values as high as 20% of bacteria, the current empiric treatment at GP level carries the risk of clinical failure and the possibility to further increase the prevalence of antibiotic resistant strains.
A point-of-care test (POCT) is defined as a diagnostic tool applicable near the site of patient care that has the potential to provide an accurate and fast diagnostic result. Several POCTs for UTI have been developed and are currently commercially available to detect the presence of bacteria or their activity in urine samples, including both culture-based and enzymatic assays, also in automated format. Existing POC tests, however, cannot provide rapid AST results during the patients first doctor visit, resulting in a delay of personalized treatment. It is the goal of the PA-100 AST System to perform a fast, automated and objective results for bacteriuria detection and AST results in less than 45 minutes and independent from the operator determination of bacteriuria and AST test.
The following investigation serves as a pilot study to better understand the potential and performance of the PA-100 Analyzer in combination with the PA-AST Panel U-0501. PA-100 AST System refers to PA-100 Analyzer in conjunction with the PA-AST Panel U-0501.
- Conditions
- UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection, AMR, Cystitis Acute, Cystitis Bacterial
- Being tested
- PA-100 AST
- Keywords
- Clinical impact investigation, PA-100 AST
- Medical subject headings
- Urinary Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PA-100 ASTDiagnostic test
Results of the PA-100 AST were made available to the treating physician
| Study group | Role | What they receive |
|---|---|---|
| Standard of Care | No intervention | Patients were managed according to local guidelines for uncomplicated community acquired urinary tract infection |
| Standard of Care with PA.100 AST | Experimental | Patients were managed according to local guidelines for uncomplicated community acquired urinary tract infection while having the additional information of PA-100 AST available during treatment decision. Receives: Diagnostic Test: PA-100 AST |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of antibiotic prescription
Measured: At initial GP visit
Secondary outcomes (1)
Type of antibiotic prescribed
Measured: At initial GP visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2025
- Study start1 Jul 2024
- Primary completion30 Jun 2025
- Study completion30 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for UTI - Urinary Tract InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 199 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sysmex Europe GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Sysmex España S.L.
- Responsible party
- Sponsor
- Investigators
- Jose Medina Polo, Principal investigator, Urología, Hospital 12 de Octubre. Servicio Madrileño de salud
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07189429
- Sponsor's protocol ID
- SEU-MSD-PA100II
- Status last verified
- Sep 2025
- First submitted
- 16 Sep 2025
- Last updated
- 24 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Not included in ethical review assesment
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PA-100 Workflow Assessment
- ClinicalTrials.gov ID
- NCT07189429
- Acronym / sponsor ID
- SEU-MSD-PA100II
- Conditions
- UTI - Urinary Tract Infection, UTI - Lower Urinary Tract Infection, AMR, Cystitis Acute, Cystitis Bacterial
- Keywords
- Clinical impact investigation, PA-100 AST
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 199 participants (actual)
- Lead sponsor
- Sysmex Europe GmbHIndustry (pharma, biotech, devices)
- Collaborators
- Sysmex España S.L.
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 30 Aug 2025 (actual)
- First posted
- 24 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assessment of workflow implications of the PA-100 AST System.
Using well-defined data collection protocols, the study comprises the following:
- Collection of clean-catch midstream urine samples
- Measurement of specimens on the PA-100 AST System
- Antibiotics tested: Amoxicillin/clavulanic acid (AMC), Ciprofloxacin (CIP), Trimethoprim (TRI), Fosfomycin (FOS) and Nitrofurantoin (NIT)
- Treatment of patients according to the results of the tests on the PA-100 AST System
- Collection of data about patient treatment and antibiotic prescription when the PA-100 AST System is not used (study baseline)
- Collection of patient related information
- Collection of workflow-related information, including doctors and nurses at the test location
- Evaluation of changes in the prescription behaviour when using the PA-100 AST System, compared to current practice at the Test Location
Detailed description
Uncomplicated cystitis in females is among the most frequent community-acquired infections. Urinary tract infection (UTI) is classified as uncomplicated if it occurs in patients with a structurally and functionally normal urinary tract in otherwise healthy, non-pregnant women. Such acute uncomplicated UTIs occur frequently and are associated with high morbidity. Approximately one third of women up to 24 years of age have experienced uncomplicated UTI.
The current gold standard for UTI diagnosis is urine culture of a midstream, clean-catch urine specimen, followed by antibiotic susceptibility testing (AST). UTI patients are often treated empirically with antibiotics, and most guidelines recommend starting antibiotic treatment without or before urine culture and AST results become available. This results in patient treatment without laboratory evidence or at least in a delay of targeted antibacterial therapy by approximately 48 h, when applicable. Due to the continually changing local rates of antimicrobial resistance, empiric treatments do not ensure appropriate stewardship and can result in therapeutic failure.
Therefore, rapid and accurate diagnosis, leading to evidence-based treatment, is essential to achieve a timely and effective therapy.
With antibiotic resistance rates for common antibiotics reaching values as high as 20% of bacteria, the current empiric treatment at GP level carries the risk of clinical failure and the possibility to further increase the prevalence of antibiotic resistant strains.
A point-of-care test (POCT) is defined as a diagnostic tool applicable near the site of patient care that has the potential to provide an accurate and fast diagnostic result. Several POCTs for UTI have been developed and are currently commercially available to detect the presence of bacteria or their activity in urine samples, including both culture-based and enzymatic assays, also in automated format. Existing POC tests, however, cannot provide rapid AST results during the patients first doctor visit, resulting in a delay of personalized treatment. It is the goal of the PA-100 AST System to perform a fast, automated and objective results for bacteriuria detection and AST results in less than 45 minutes and independent from the operator determination of bacteriuria and AST test.
The following investigation serves as a pilot study to better understand the potential and performance of the PA-100 Analyzer in combination with the PA-AST Panel U-0501. PA-100 AST System refers to PA-100 Analyzer in conjunction with the PA-AST Panel U-0501.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Standard of Care | No intervention | –Patients were managed according to local guidelines for uncomplicated community acquired urinary tract infection |
| Standard of Care with PA.100 AST | Experimental | Diagnostic Test: PA-100 ASTPatients were managed according to local guidelines for uncomplicated community acquired urinary tract infection while having the additional information of PA-100 AST available during treatment decision. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients were recruited according to the following criteria: non-pregnant female, >18 years old, presenting with acute UTI symptoms that had been present for < 7 days (symptoms according to the current guidelines [EAU]), with no antibiotic treatment within the previous 7 days, positive urine dipstick for leukocyte esterase (LEU) and/or nitrites (NIT) and who provided a clean-catch mid-stream urine sample.
Key exclusion criteria (1 listed)
- Withdraw of consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PA-100 ASTResults of the PA-100 AST were made available to the treating physician | Diagnostic test | Standard of Care with PA.100 AST |
Primary outcome
Frequency of antibiotic prescription
Time frame: At initial GP visit
1 secondary outcome
Type of antibiotic prescribed
Time frame: At initial GP visit
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2025.
- Individual participant dataSharing planned: No. Not included in ethical review assesment
Related trials for UTI - Urinary Tract Infection
Recruiting
Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture
Urinary Tract Infections
Active, not recruitingObservational study
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
Complicated Urinary Tract Infection
Recruiting
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS
Drug Resistance, Microbial, Biomarkers
Not yet recruitingObservational study
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
Urinary Tract Infections
Active, not recruitingObservational study
Characterization of Vaginal, Urinary and Fecal Microbiomes in Women With Recurrent Urinary Tract Infections
Urinary Tract Infections, Menopause
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jose Medina Polo principal investigator
Urología, Hospital 12 de Octubre. Servicio Madrileño de salud
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PA-100 AST in people with UTI - Urinary Tract Infection and UTI - Lower Urinary Tract Infection, run by Sysmex Europe GmbH at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency of antibiotic prescription (time frame: At initial GP visit). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2025.